350 rub
Journal №4 for 2011 г.
Article in number:
Postponed effects of neonatal chronical arginine-vasopressin and its structural analogue Ac-D-Met-Pro-Arg-Gly-NH2 administration on exploratory activity and anxiety level in white rats
Authors:
Р.А. Кim, O.G. Voskresenskaya, A.A. Kamensky, V.P. Martinovich, V.P. Golubovich
Abstract:
Effects of arguinine-vasopressin (AVP) and its structural synthetic analogue Ac-D-MPRG on the white rats exploratory activity and anxiety level were studied. Peptides were administrated chronically from the 8th to the 14th days of life intranasally in the following doses: AVP - 10 mcg per kg, Ac-D-MPRG - 10 and 0,01 mcg per kg. AVP and its analogue in big dose have a pronounced anxiolytic effect in adolescent and adult rats, and both of them also decrease the level of animal emotional tensity in all age-specific groups. Administration of Ac-D-MPRG in the dose of 0,01 mcg per kg doesn-t have relative effects on anxiety-like behavior. AVP hasn-t effects on exploratory activity in both unstress and stress conditions. In the same time Ac-D-MPRG influence on this type of behavior in unstress conditions: in the dose of 10 mcg per kg it decreases the level of exploratory activity of adolescent rats and during the puberty, and in dose 0,01 mcg per kg AVP analogue has opposite effects. These changes are made conditional upon modulations of vertical and no horizontal locomotor activity. In the stress conditions effects of Ac-D-MPRG in the small dose are relative to those in the unstress environment, and in the large dose it has its own specific effects. So, in adolescent rats it increases horizontal locomotor activity, during the puberty it decreases level of exploratory behavior and has no influence on adult animals. In conclusion we can say that neonatal chronical administration of AVP and Ac-D-MPRG had postponed behavioral effects of relative direction in white rats depending on their age and on the dose of pharmacological agent.
Pages: 17-23
References
  1. Baranowska D., Braszko J.J., Wisniwski K. Effect of angiotensin II and vasopressin on acquisition and extinction of conditioned avoidance in rats // Psychopharmacology, 1983. 81. № 3. Р. 247-251.
  2. Bielsky I.F., Hu S.B., Szegda K.L., Westphal H., Young L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice // Neuropsychopharmacology. 2004. V. 29. P. 483-493.
  3. Everts H.G.J., Koolhaas J.M. Differential modulation of lateral septal vasopressin receptor blockade in spatial learning, social recognition, and anxiety-related behaviors in rats // Behav. Brain Res. 1999. V. 99. P. 7-16.
  4. Пономарева Н.С., Воскресенская О.Г., Каменский А.А., Голубович В.П., Ашмарин И.П. Влияние оригинального аналога С-концевого фрагмента вазопрессина на поведение белых крыс // Журнал ВНД. 1998. Т. 48. № 3. С. 471-477.
  5. Пономарева Н.С., Воскресенская О.Г., Каменский А.А., Голубович В.П., Ашмарин И.П. Улучшение селективного восприятия и обучения крыс оригинальным аналогом С-концевого фрагмента вазопрессина // Рос. физиол. журн. им. Сеченова. 1998. Т. 84. № 12. С. 1363-1369.
  6. Воскресенская О.Г., Голубович В.П., Запольский М.Э., Каменский А.А. Влияние хронического постнатального введения аргинин-вазопрессина и его С-концевого аналога на ориентировочно-исследовательское поведение и уровень тревожности белых крыс // Вестник Моск. Ун-та. Сер.16. Биология. 2002. № 1. С. 3-7 .
  7. Воскресенская О.Г., Каменский А.А., Голубович В.П. Нейротропная активность синтетического аналога С-концевого фрагмента аргинин-вазопрессина // News of Biomedical Sciences. 2004. № 1. С. 72-78.
  8. Угрюмов М.В. Механизмы нейроэндокринной регуляции. М. 1999. С. 54-72.
  9. De Vries G.J., Miller M.A. Anatomy and function of extrahypothalamic vasopressin systems in the brain // Prod. Brain Res. 1998. V. 119. P. 3-20.
  10. Hernando F., Shoots O., Lolait S.J., Вurbach J.P.H. Immunohistochemical Localization of the Vasopressin V1b Receptor in the Rat Brain and Pituitary Gland: Anatomical Support for Its Involvement in the Central Effects of Vasopressin // Endocrinology. 2001. V. 142(4). P. 1659-1668.